Barron’s

Co-portfolio manager Roy Behren explains why perceived regulatory risk may be negatively weighing on Fitbit’s share price in Max Cherney’s Barron’s piece, “With Google Deal in Doubt, Fitbit’s Stock Looks Cheap.”